Saloni (on behalf of Andrea Newkirk)'s questions to Abcellera Biologics Inc (ABCL) leadership • Q1 2025
Question
Saloni from Goldman Sachs, on for Andrea Newkirk, asked for any precedent that supports the translatability of preclinical NK3R engagement for ABCL635 into human clinical settings. She also inquired about the company's strategy for selecting its next development candidates beyond the two lead programs.
Answer
President and CEO Dr. Carl L. Hansen acknowledged that while preclinical NHP data is optimistic, translation to humans is a key risk that must be proven. He noted some precedent with antibodies targeting similar brain regions but stressed that the Phase I biomarker and efficacy data for ABCL635 are designed to derisk this early. Regarding future candidates, Dr. Hansen explained that AbCellera is target-agnostic, focusing on high-conviction biology and a clear development path. He indicated the next candidate will likely emerge from the GPCR or ion channel platform, with target disclosure depending on the competitive landscape.